Causal association of metabolic syndrome with chronic kidney disease progression: A Mendelian randomization study

Abstract

Research from the past has indicated a link between the risk of chronic kidney disease (CKD) and metabolic syndrome (MetS). It is yet unknown. Nevertheless, exactly how the dynamic process of declining renal function and metabolic syndrome are related. The study’s purpose is to evaluate the causal relationship between MetS and the deterioration in kidney function using a Mendelian randomization (MR). Univariable and multivariable MR were applied to evaluate the causal relationships between MetS and its components with Rapid3, CKDi25, and CKD. The main source of MetS data was the GTC database, whose constituents came from extensive genome-wide association research. The CKDGen Consortium provided data on dynamic changes in kidney function. Preliminary analysis was conducted using five different statistical techniques, including Inverse Variance Weighting and Weighted Median. Rucker’s Q, MR-Egger, and Cochran’s Q test were used in sensitivity studies. In order to address reverse causality, the Steiger test was used. The IVW results showed Rapid3, CKDi25, and CKD all exhibited positive correlations with MetS. Rapid3, CKDi25, and CKD were found to have a positive causal relationship with SBP and WC, while DBP was also linked to an increased risk of Rapid3 and CKDi25. Even after accounting for other variables, MVMR analysis showed a correlation between WC and the drop in kidney function indices. MetS, together with its constituents WC, SBP, and DBP, are separate risk factors for the deterioration of renal function. However, the causal relationship between FBG, HDL, TG, and the decline in kidney function indicators remains uncertain.

Keywords

chronic kidney disease / Mendelian randomization / metabolic syndrome

References

[1] KovesdyCP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022; 12(1):7-11.

[2] WebsterAC, NaglerEV, MortonRL, Masson P. Chronic kidney disease. Lancet. 2017; 389(10075):1238-1252.

[3] RomagnaniP, Remuzzi G, GlassockR, et al. Chronic kidney disease. Nat Rev Dis Prim. 2017; 3(1):17088.

[4] MuntnerP, CoreshJ, SmithJC, Eckfeldt J, KlagMJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000; 58(1):293-301.

[5] ShankarA, KleinR, KleinBEK. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006; 164(3):263-271.

[6] CornierMA, Dabelea D, HernandezTL, et al. The metabolic syndrome. Endocr Rev. 2008; 29(7):777-822.

[7] PanJ, WangM, YeZ, et al. Optimal cut-off levels of obesity indices by different definitions of metabolic syndrome in a southeast rural Chinese population. J Diabetes Investig. 2016; 7(4):594-600.

[8] HirodeG, WongRJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-2528.

[9] KurellaM, LoJC, ChertowGM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005; 16(7):2134-2140.

[10] LucoveJ, Vupputuri S, HeissG, NorthK, Russell M. Metabolic syndrome and the development of CKD in American Indians: the strong heart study. Am J Kidney Dis. 2008; 51(1):21-28.

[11] CiardulloS, Ballabeni C, TrevisanR, PerseghinG. Metabolic syndrome, and not obesity, is associated with chronic kidney disease. Am J Nephrol. 2021; 52(8):666-672.

[12] SinghAK, KariJA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013; 22(2):198-203.

[13] ZomorrodianD, Khajavi-Rad A, AvanA, et al. Metabolic syndrome components as markers to prognosticate the risk of developing chronic kidney disease: evidence-based study with 6492 individuals. J Epidemiol Community Health. 2015; 69(6):594-598.

[14] SmithGD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004; 33(1):30-42.

[15] SmithGD. Mendelian randomization for strengthening causal inference in observational studies: application to gene × environment interactions. Perspect Psychol Sci. 2010; 5(5):527-545.

[16] PingaultJB, O’Reilly PF, SchoelerT, PloubidisGB, Rijsdijk F, DudbridgeF. Using genetic data to strengthen causal inference in observational research. Nat Rev Genet. 2018; 19(9):566-580.

[17] BoefAGC, Dekkers OM, le CessieS. Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015; 44(2):496-511.

[18] van WalreeES, JansenIE, BellNY, et al. Disentangling genetic risks for metabolic syndrome. Diabetes. 2022; 71(11):2447-2457.

[19] LinY-W, ZhouC, WuY-Q, Chen H, XieL-P, ZhengX-Y. Mendelian randomization analysis reveals fresh fruit intake as a protective factor for urolithiasis. Hum Genom. 2023; 17(1):89.

[20] HanX, WuT, LiuCY. Univariable and multivariable Mendelian randomization investigating the effects of telomere length on the risk of adverse pregnancy outcomes. Front Endocrinol. 2023; 14:1225600.

[21] WuttkeM, LiY, LiM, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019; 51(6):957-972.

[22] GorskiM, JungB, LiY, et al. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. Kidney Int. 2021; 99(4):926-939.

[23] PierceBL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013; 178(7):1177-1184.

[24] BowdenJ, Davey Smith G, HaycockPC, BurgessS. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted Median estimator. Genet Epidemiol. 2016; 40(4):304-314.

[25] BowdenJ, Davey Smith G, BurgessS. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015; 44(2):512-525.

[26] HartwigFP, Davey Smith G, BowdenJ. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017; 46(6):1985-1998.

[27] Fabiola GrecoM, Minelli C, SheehanNA, ThompsonJR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015; 34(21):2926-2940.

[28] BowdenJ, Del Greco MF, MinelliC, Davey SmithG, Sheehan N, ThompsonJ. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017; 36(11):1783-1802.

[29] HemaniG, Tilling K, Davey SmithG. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017; 13(11):e1007081.

[30] BrionMJA, Shakhbazov K, VisscherPM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013; 42(5):1497-1501.

[31] GrantAJ, Burgess S. Pleiotropy robust methods for multivariable Mendelian randomization. Stat Med. 2021; 40(26):5813-5830.

[32] Muñoz-VargasMA, González-Gordo S, TaboadaJ, PalmaJM, CorpasFJ. In silico RNAseq and biochemical analyses of glucose-6-phosphate dehydrogenase (G6PDH) from sweet pepper fruits: involvement of nitric oxide (NO) in ripening and modulation. Plants. 2023; 12(19):3408.

[33] ScurtFG, GanzMJ, HerzogC, Bose K, MertensPR, ChatzikyrkouC. Association of metabolic syndrome and chronic kidney disease. Obes Rev. 2024; 25(1):e13649.

[34] NavaneethanSD, ScholdJD, KirwanJP, et al. Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol. 2013; 8(6):945-952.

[35] WatanabeH, ObataH, WatanabeT, Sasaki S, NagaiK, AizawaY. Metabolic syndrome and risk of development of chronic kidney disease: the Niigata preventive medicine study. Diabetes Metab Res Rev. 2010; 26(1):26-32.

[36] KazancioğluR. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 2013; 3(4):368-371.

[37] KotsisV, Martinez F, TrakatelliC, RedonJ. Impact of obesity in kidney diseases. Nutrients. 2021; 13(12):4482.

[38] LeeJY, ParkJT, JooYS, et al. Association of blood pressure with the progression of CKD: findings from KNOW-CKD study. Am J Kidney Dis. 2021; 78(2):236-245.

[39] MendyVL, Azevedo MJ, SarpongDF, et al. The association between individual and combined components of metabolic syndrome and chronic kidney disease among African Americans: the Jackson Heart Study. PLoS One. 2014; 9(7):e101610.

[40] AlbertiKGMM, ZimmetP, ShawJ. Metabolic syndrome: a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006; 23(5):469-480.

RIGHTS & PERMISSIONS

2024 The Author(s). Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children’s Hospital of Chongqing Medical University.